vs
Side-by-side financial comparison of CURTISS WRIGHT CORP (CW) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.
CURTISS WRIGHT CORP is the larger business by last-quarter revenue ($947.0M vs $878.4M, roughly 1.1× EXACT SCIENCES CORP). CURTISS WRIGHT CORP runs the higher net margin — 14.5% vs -9.8%, a 24.3% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 14.9%). CURTISS WRIGHT CORP produced more free cash flow last quarter ($315.1M vs $120.4M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs 15.2%).
The Curtiss-Wright Corporation is an American manufacturer and services provider headquartered in Davidson, North Carolina, with factories and operations in and outside the United States. Created in 1929 from the consolidation of Curtiss, Wright, and various supplier companies, the company was immediately the country's largest aviation firm and built more than 142,000 aircraft engines for the U.S. military during World War II.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
CW vs EXAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $947.0M | $878.4M |
| Net Profit | $137.0M | $-86.0M |
| Gross Margin | 37.5% | 70.1% |
| Operating Margin | 19.2% | -9.4% |
| Net Margin | 14.5% | -9.8% |
| Revenue YoY | 14.9% | 23.1% |
| Net Profit YoY | 16.2% | 90.1% |
| EPS (diluted) | $3.69 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $947.0M | $878.4M | ||
| Q3 25 | $869.2M | $850.7M | ||
| Q2 25 | $876.6M | $811.1M | ||
| Q1 25 | $805.6M | $706.8M | ||
| Q4 24 | $824.3M | $713.4M | ||
| Q3 24 | $798.9M | $708.7M | ||
| Q2 24 | $784.8M | $699.3M | ||
| Q1 24 | $713.2M | $637.5M |
| Q4 25 | $137.0M | $-86.0M | ||
| Q3 25 | $124.8M | $-19.6M | ||
| Q2 25 | $121.1M | $-1.2M | ||
| Q1 25 | $101.3M | $-101.2M | ||
| Q4 24 | $117.9M | $-864.6M | ||
| Q3 24 | $111.2M | $-38.2M | ||
| Q2 24 | $99.5M | $-15.8M | ||
| Q1 24 | $76.5M | $-110.2M |
| Q4 25 | 37.5% | 70.1% | ||
| Q3 25 | 37.7% | 68.6% | ||
| Q2 25 | 37.2% | 69.3% | ||
| Q1 25 | 36.3% | 70.8% | ||
| Q4 24 | 38.5% | 69.0% | ||
| Q3 24 | 37.3% | 69.4% | ||
| Q2 24 | 36.2% | 69.8% | ||
| Q1 24 | 35.6% | 70.0% |
| Q4 25 | 19.2% | -9.4% | ||
| Q3 25 | 19.1% | -3.0% | ||
| Q2 25 | 17.8% | -0.3% | ||
| Q1 25 | 16.0% | -13.6% | ||
| Q4 24 | 18.8% | -122.8% | ||
| Q3 24 | 18.1% | -5.6% | ||
| Q2 24 | 16.4% | -3.8% | ||
| Q1 24 | 14.0% | -16.7% |
| Q4 25 | 14.5% | -9.8% | ||
| Q3 25 | 14.4% | -2.3% | ||
| Q2 25 | 13.8% | -0.1% | ||
| Q1 25 | 12.6% | -14.3% | ||
| Q4 24 | 14.3% | -121.2% | ||
| Q3 24 | 13.9% | -5.4% | ||
| Q2 24 | 12.7% | -2.3% | ||
| Q1 24 | 10.7% | -17.3% |
| Q4 25 | $3.69 | $-0.45 | ||
| Q3 25 | $3.31 | $-0.10 | ||
| Q2 25 | $3.19 | $-0.01 | ||
| Q1 25 | $2.68 | $-0.54 | ||
| Q4 24 | $3.09 | $-4.69 | ||
| Q3 24 | $2.89 | $-0.21 | ||
| Q2 24 | $2.58 | $-0.09 | ||
| Q1 24 | $1.99 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $964.7M |
| Total DebtLower is stronger | $957.9M | — |
| Stockholders' EquityBook value | $2.5B | $2.4B |
| Total Assets | $5.2B | $5.9B |
| Debt / EquityLower = less leverage | 0.38× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $964.7M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $858.4M | ||
| Q1 25 | $226.5M | $786.2M | ||
| Q4 24 | $385.0M | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $946.8M | ||
| Q1 24 | $338.0M | $652.1M |
| Q4 25 | $957.9M | — | ||
| Q3 25 | $968.6M | — | ||
| Q2 25 | $958.4M | — | ||
| Q1 25 | $958.6M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $2.5B | $2.4B | ||
| Q3 25 | $2.5B | $2.5B | ||
| Q2 25 | $2.7B | $2.5B | ||
| Q1 25 | $2.6B | $2.4B | ||
| Q4 24 | $2.4B | $2.4B | ||
| Q3 24 | $2.5B | $3.2B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.4B | $3.1B |
| Q4 25 | $5.2B | $5.9B | ||
| Q3 25 | $5.1B | $5.9B | ||
| Q2 25 | $5.2B | $5.8B | ||
| Q1 25 | $5.0B | $5.7B | ||
| Q4 24 | $5.0B | $5.9B | ||
| Q3 24 | $4.9B | $6.7B | ||
| Q2 24 | $4.7B | $6.7B | ||
| Q1 24 | $4.6B | $6.4B |
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.42× | — | ||
| Q2 24 | 0.43× | — | ||
| Q1 24 | 0.44× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $352.7M | $151.7M |
| Free Cash FlowOCF − Capex | $315.1M | $120.4M |
| FCF MarginFCF / Revenue | 33.3% | 13.7% |
| Capex IntensityCapex / Revenue | 4.0% | 3.6% |
| Cash ConversionOCF / Net Profit | 2.57× | — |
| TTM Free Cash FlowTrailing 4 quarters | $553.7M | $356.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $352.7M | $151.7M | ||
| Q3 25 | $192.8M | $219.9M | ||
| Q2 25 | $136.6M | $89.0M | ||
| Q1 25 | $-38.8M | $30.8M | ||
| Q4 24 | $301.3M | $47.1M | ||
| Q3 24 | $177.3M | $138.7M | ||
| Q2 24 | $111.3M | $107.1M | ||
| Q1 24 | $-45.6M | $-82.3M |
| Q4 25 | $315.1M | $120.4M | ||
| Q3 25 | $175.9M | $190.0M | ||
| Q2 25 | $117.2M | $46.7M | ||
| Q1 25 | $-54.5M | $-365.0K | ||
| Q4 24 | $278.0M | $10.7M | ||
| Q3 24 | $162.7M | $112.6M | ||
| Q2 24 | $100.3M | $71.2M | ||
| Q1 24 | $-57.7M | $-120.0M |
| Q4 25 | 33.3% | 13.7% | ||
| Q3 25 | 20.2% | 22.3% | ||
| Q2 25 | 13.4% | 5.8% | ||
| Q1 25 | -6.8% | -0.1% | ||
| Q4 24 | 33.7% | 1.5% | ||
| Q3 24 | 20.4% | 15.9% | ||
| Q2 24 | 12.8% | 10.2% | ||
| Q1 24 | -8.1% | -18.8% |
| Q4 25 | 4.0% | 3.6% | ||
| Q3 25 | 1.9% | 3.5% | ||
| Q2 25 | 2.2% | 5.2% | ||
| Q1 25 | 2.0% | 4.4% | ||
| Q4 24 | 2.8% | 5.1% | ||
| Q3 24 | 1.8% | 3.7% | ||
| Q2 24 | 1.4% | 5.1% | ||
| Q1 24 | 1.7% | 5.9% |
| Q4 25 | 2.57× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 1.13× | — | ||
| Q1 25 | -0.38× | — | ||
| Q4 24 | 2.56× | — | ||
| Q3 24 | 1.59× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | -0.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CW
| Naval Power | $417.4M | 44% |
| Defense Electronics | $268.3M | 28% |
| Aerospace Industrial | $262.4M | 28% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
